Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 4M | 299K | 292K | 9K |
| Gross Profit | 39K | 299K | 292K | 9K |
| Operating Income | -38M | -37M | -35M | -20M |
| EBITDA | -38M | -44M | -31M | -18M |
| Net Income | -38M | -48M | -35M | -30M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$4.45
+0.79% today
1Y Change
-2.73%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Radiopharm Theranostics Limited (RADX) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $4.45 and down 2.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +1114.3%, EPS growth of +85.3%, a dividend yield of 0.0%. What stands out right now is revenue +1114.3%, EPS +85.3%, free cash flow -59.5% with operating margin -1050.6% and ROIC -53.4%. Valuation is more restrained than many high-expectation growth names at price/sales 2.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RADX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RADX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RADX Max Drawdown
-62.37%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RADX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.8K
-97.0% YoY
FY Net Income
-$30.3M
+12.3% YoY
Free Cash Flow
-$38.3M
-54.7% YoY
Revenue Growth
+1114.3%
EPS Growth
+85.3%
Gross Margin
1.1%
Net Margin
-1055.3%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 4M | 299K | 292K | 9K |
| Gross Profit | 39K | 299K | 292K | 9K |
| Operating Income | -38M | -37M | -35M | -20M |
| EBITDA | -38M | -44M | -31M | -18M |
| Net Income | -38M | -48M | -35M | -30M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 29M | 19M | 12M | 27M |
| Total Assets | 86M | 72M | 75M | 83M |
| Total Liabilities | 44M | 45M | 29M | 20M |
| Shareholder Equity | 45M | 28M | 44M | 63M |
| Total Debt | 0 | 0 | 0 | 0 |
| Net Debt | -29M | -19M | -12M | -27M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10M
+57.3% YoY
Capital Expenditures
28M
-1751.4% YoY
Free Cash Flow
38M
-54.7% YoY
Key ratios
Gross Margin
1.1%
Operating Margin
-1050.6%
Net Margin
-1055.3%
ROE
-105.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.